Eli Lilly Stock Jumps 6% on 48% Revenue Surge - The Exact Opposite of Novo Nordisk's Reaction a Day Earlier

What Happened

Before the opening bell on August 5, Eli Lilly (LLY) reported second-quarter results that, on paper, were about as clean a beat as a company can post.

• Revenue: $23.0 billion, up 48% year-over-year, well ahead of the roughly $20.9 billion analysts expected
• Adjusted EPS: $8.38, sharply above the consensus estimate of around $6
• Mounjaro (diabetes): $9.9 billion in sales, up 91% year-over-year
• Zepbound (obesity): $4.9 billion in US sales, up 44% year-over-year
• Foundayo, the oral obesity pill approved in April, generated roughly $98 million in its first full quarter, coming in slightly below the roughly $103 million analysts had expected

On the back of those numbers, Lilly raised its full-year revenue guidance from $82-85 billion to $85-87 billion and lifted its adjusted EPS outlook to $35.50-$36.50. Revenue, profit, and flagship product growth all came in above what the Street was looking for.

The stock reaction matched the numbers. Lilly shares jumped roughly 6% Wednesday, climbing back toward record territory. That's the mirror image of what happened just one day earlier: GLP-1 rival Novo Nordisk also raised its full-year guidance - and its stock fell more than 6% (see our related coverage). Same week, same sector, the same headline ("guidance raised") - and completely opposite stock reactions.

Why the Same Headline Produced Opposite Reactions

• The substance behind each guidance raise was completely different. Novo's improved outlook came largely from stronger sales volumes outside the US, while its most closely watched number - US sales of its flagship Wegovy - fell 22% as price cuts outpaced volume gains. Lilly's raise was backed by genuine, volume-driven growth on both fronts: Mounjaro sales up 91%, Zepbound's US sales up 44%. A "guidance raise" headline can mean growth propped up mostly by volume absorbing a price cut, or growth from demand actually expanding - and the market grades those two very differently.
• Competitive standing gets priced in alongside the numbers themselves. Lilly shares are up more than 50% over the past year, extending a run in which the company has increasingly pulled ahead of Novo in the GLP-1 market. This report reaffirmed that lead with hard numbers, and the market rewarded genuine growth that widens a competitive gap more generously than it would reward the same growth in isolation.
• A real miss in one product line didn't outweigh dominant results everywhere else. Foundayo's sales came in slightly short of estimates. But with revenue, EPS, and flagship product growth all beating by a wide margin, one modest miss in a newer, smaller product wasn't enough to flip the overall reaction.

What to Take Away From This

• Don't just read the "guidance raised" headline - trace where the growth actually came from. Novo and Lilly both raised guidance within a day of each other, yet their stocks moved in opposite directions. Missing the difference between volume-driven growth and growth that's merely offsetting a price cut means missing why the market reacted so differently to two similar-sounding headlines.
• Comparing earnings reactions across an entire sector reveals sentiment that a single company's numbers can't. Novo Nordisk and Lilly diverged sharply within the same week for reasons rooted in the same underlying metric - US sales growth. When evaluating any stock in a competitive sector, check how its results compare with a close rival's, not just against its own guidance.
• Don't let one small miss define your read of an entire earnings report. Foundayo's shortfall doesn't make this a disappointing quarter. When the headline numbers are dominant, a modest miss in a secondary line item usually isn't enough to change the overall picture.

For related context, see: Novo Nordisk Stock Falls 6% Despite Raised Guidance, Dow Tops 54,000 for the First Time on Caterpillar's Earnings Beat

Sources

This article synthesizes and analyzes the reporting below in our own words - it is not a reproduction of the original text. For the latest figures and full detail, please refer to the original sources.

• Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge - CNBC
• Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast - Quartz
• Lilly reports second-quarter 2026 financial results, raises full-year guidance - Eli Lilly Investor Relations

⚠️ This article is for informational purposes only and is not investment advice. Market conditions change constantly - always verify the latest data yourself before making any investment decision.